Clinical trials: Botulinum toxin type A
Muscle Spasticity
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)
The purpose of this study is to evaluate the safety and pharmacodynamic of CORETOX® in the treatment of post-stroke upper limb spasticity
- Trial name
- NCT05164003
- Testing
- CORETOX®, BOTOX®
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label…
- Trial name
- NCT04143815
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement…
- Trial name
- NCT02450526
- Testing
- Botulinum toxin type A
- Where
- 10 sites in China
- Volunteers
- 520 people
- Sponsor
- Ipsen
Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as…
- Trial name
- BOREAL (NCT02673047)
- Testing
- botulinum toxin Type A
- Where
- 50 sites in France
- Volunteers
- 474 people
- Sponsor
- Allergan
Chronic Scar Pain
Dysport in Post-Surgical Neuralgia
The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous…
- Trial name
- PMOD03 (NCT03663101)
- Testing
- Lidocaine, Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Ipsen
Glabellar Lines
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.
- Trial name
- NCT05428930
- Testing
- CKDB-501B, Botox®50U
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- CKD Bio Corporation
Glabellar Frown Lines
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT03440671
- Testing
- Hutox Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Huons Co., Ltd.
Upper Limb Spasticity
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT05956509
- Testing
- ABBV-950, BOTOX
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Hyperhidrosis Primary Focal Axilla
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.
- Trial name
- NCT03760198
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Injection Site Discomfort
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
- Trial name
- NCT06161246
- Testing
- Vibrating Beauty Bar
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Spasticity, Post-Stroke
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.
- Trial name
- NCT01205451
- Testing
- Botulinum toxin type A
- Where
- 13 sites in China
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Photoaging, Wrinkle
Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles
This study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. VI Peels® and Botox® have been used cosmetically to improve patient concerns as monotherapies.
- Conditions
- Photoaging, Wrinkle, Sun Damaged Skin
- Trial name
- NCT05162300
- Testing
- Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vitality Institute Medical Products
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Drooling
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
- Trial name
- NCT00515437
- Testing
- Botulinum Toxin Type B (Myobloc)
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Moderate to Severe Glabellar Lines
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 3, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate the efficacy and safety of 50 units (U) of QM1114-DP for the treatment of moderate to severe GL in male and…
- Trial name
- NCT05463965
- Testing
- QM1114-DP, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie